APAC anti-aging capital is pricing a regulatory category that does not exist. PMDA's pharmaceutical affairs division, NMPA's Center for Drug Evaluation, TGA's Advisory Committee on Medicines, and Singapore's Health Sciences Authority have each approved drugs for age-related diseases. None has approved a compound for biological aging as a primary indication. None has publicly committed to doing so. The capital running into Singapore and Hong Kong anti-aging biotech rounds between 2024 and Q2 2026 is not priced as venture-stage option exposure. It is priced as category creation, expected 2025 or 2026.

The TAME trial is Phase 3, 3,000 adults aged 65-79, primary composite endpoint of incident cardiovascular disease, cancer, dementia, and all-cause mortality. It is the only study in any jurisdiction designed to generate the evidence base a regulatory anti-aging designation would require. Enrollment opened in 2023. The endpoint accrues slowly by design: the trial recruited healthy elderly adults precisely because the signal of genuine aging modification would show in long-term outcome data, not in surrogate endpoints at 12 months. My read is that the current APAC positioning is underwriting a 2026 regulatory event on the basis of a trial that the AFAR and NIH are funding to read out in 2028. The capital is pricing 2026. The science delivers 2028, at the earliest, with no guarantee that metformin moves the composite at the effect size the trial was powered to detect.